ArticleAnnals of hematology2025
Prognostic potential of albumin to fibrinogen ratio in multiple myeloma patients.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The albumin/fibrinogen ratio is a cheap, simple, useful and independent biological marker used in several clinical disorders. Particularly, it has been evaluated in different types of malignant neoplasms and in this regard, in recent years, many researchers have focused this topic. In this paper, we examined the behaviour of this parameter in a cohort of newly diagnosed multiple myeloma patients. The study population includes 190 patients (mean age of 69+/- 10 years of which 88 were women and 102 were men) in which the albumin/fibrinogen ratio was determined at the time of diagnosis and the study enrolment. We have examined this ratio in relation to different anthropometric and prognostic parameters, but also to survival. Our results show that this ratio is significantly influenced by the sex, the hematocrit values, the hemoglobin levels, the beta-2 microglobulin, the red cell distribution width and RDW/albumin ratio. Instead, it is not affected by age, RDW/hemoglobin ratio, LDH values and the bone marrow plasma cell infiltration. Moreover, we observed a marked difference in this ratio between surviving and deceased MM patients. The obtained data, although preliminary, may help to understand the complexity of multiple myeloma, especially in the field of the prognostic evaluation, and they could suggest a role for the albumin/fibrinogen ratio as an additional biomarker of multiple myeloma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.